Navidea stock analysis
Navidea (NAVBQ) Stock Price & Analysis
NAVBQ Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- $0.01 - $0.04
- Previous Close
- $0.04
- Volume
- N/A
- Average Volume (3M)
- 55.60K
- Market Cap
- $10.01K
- Enterprise Value
- $449.76B
- Total Cash (Recent Filing)
- $3.86M
- Total Debt (Recent Filing)
- $1.26M
- Price to Earnings (P/E)
- 0.0
- Beta
- -161.88
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
NAVBQ FAQ
What was Navidea’s price range in the past 12 months?
What is Navidea’s market cap?
When is Navidea’s upcoming earnings report date?
How were Navidea’s earnings last quarter?
Is Navidea overvalued?
Does Navidea pay dividends?
What is Navidea’s EPS estimate?
How many shares outstanding does Navidea have?
What happened to Navidea’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Navidea?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Navidea
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to advancing and commercializing specialized agents for immunodiagnosis and innovative immunotherapeutics. The company operates across two distinct segments: Diagnostic Substances and Therapeutic Development Programs. Its core technology, the Manocept platform, is designed to target the CD206 mannose receptor, which is prominently found on activated macrophages. This platform enables a variety of diagnostic imaging techniques, including single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and both intra-operative and optical-fluorescence detection methods. Beyond diagnostics, Manocept also facilitates the targeted delivery of therapeutic compounds to macrophages, addressing diseases characterized by immune system involvement and inflammation. Among its key pipeline assets, NAV3-31 has successfully completed Phase IIb clinical trials. These trials assessed the imaging repeatability, reproducibility, and stability, along with the effectiveness of Tc99m tilmanocept imaging in monitoring anti-tumor necrosis factor alpha therapy for patients with moderate to severe rheumatoid arthritis (RA). NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials, also for RA. Furthermore, NAV3-32 is participating in a Phase 2b trial specifically for RA-involved joints. The company is also exploring the utility of Tc99m tilmanocept in other therapeutic areas, such as cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and various other immunotherapeutic applications. Originally established as Neoprobe Corporation, the company officially adopted the name Navidea Biopharmaceuticals, Inc. in January 2012. Founded in 1983, its corporate headquarters are situated in Dublin, Ohio. In a significant corporate development, Navidea Biopharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 with the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig A. Dais
- Employees
- 11
- Website
- www.navidea.com
- Address
- 4995 Bradenton Avenue, Dublin, OH, 43017-3552, US
